Contribution of organic anion transporting polypeptide (OATP) 1B1 and OATP1B3 to hepatic uptake of nateglinide, and the prediction of drug-drug interactions via these transporters

Journal of Pharmacy and Pharmacology

Volumn 64, Issue 2, 2012, Pages 199-206

  Takanohashi, Toshiyuki ^a   Kubo, Satoru ^a   Arisaka, Harumi ^a   Shinkai, Kenji ^a   Ubukata, Kazuyuki ^a  

^a AJINOMOTO CO INC   (Japan)

Author keywords

drug drug interaction; nateglinide; OATP1B3; organic anion transporting polypeptide (OATP) 1B1

Indexed keywords

CHOLECYSTOKININ OCTAPEPTIDE; CYCLOSPORIN A; ESTRONE SULFATE; MEMBRANE PROTEIN; NATEGLINIDE; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B1; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B3; REPAGLINIDE; RIFAMPICIN; UNCLASSIFIED DRUG;

ARTICLE; CELL METABOLISM; CELL STRAIN HEK293; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYOPRESERVATION; DRUG CLEARANCE; DRUG EFFECT; DRUG INHIBITION; DRUG UPTAKE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LIVER METABOLISM; PROTEIN EXPRESSION; PROTEIN FUNCTION;

BIOLOGICAL TRANSPORT; CELLS, CULTURED; CYCLOHEXANES; DRUG INTERACTIONS; HEPATOCYTES; HUMANS; HYPOGLYCEMIC AGENTS; MODELS, THEORETICAL; ORGANIC ANION TRANSPORTERS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; PHENYLALANINE; TIME FACTORS;

EID: 84855445288     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2011.01389.x     Document Type: Article

References (33)

1. Ikenoue T, et al,. Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (-)-N-(trans- 4-isopropylcyclohexanecarbonyl)-D- phenylalanine (A-4166). Br J Pharmacol 1997; 120: 137-145. (Pubitemid 27042572)
2. Ikenoue T, et al,. Effect of a new hypoglycemic agent, A-4166 [(-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine], on postprandial blood glucose excursion: comparison with voglibose and glibenclamide. Biol Pharm Bull 1997; 20: 354-359. (Pubitemid 27212992)
3. McLeod JF,. Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent. Clin Pharmacokinet 2004; 43: 97-120. (Pubitemid 38283133)
4. Takanohashi T, et al,. Inhibition of human liver microsomal CYP by nateglinide. J Pharm Pharmacol 2010; 62: 592-597.
5. Takanohashi T, et al,. Prediction of the metabolic interaction of nateglinide with other drugs based on in vitro studies. Drug Metab Pharmacokinet 2007; 22: 409-418.
6. Niemi M, et al,. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther 2005; 77: 468-478. (Pubitemid 40824960)
7. Kalliokoski A, et al,. Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. J Clin Pharmacol 2008; 48: 311-321. (Pubitemid 351257770)
8. Abe T, et al,. Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem 1999; 274: 17159-17163.
9. Abe T, et al,. LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology 2001; 120: 1689-1699. (Pubitemid 32523487)
10. Hsiang B, et al,. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 1999; 274: 37161-37168.
11. König J, et al,. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol 2000; 278: G156-G164. (Pubitemid 30108080)
12. König J, et al,. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J Biol Chem 2000; 275: 23161-23168. (Pubitemid 30646210)
13. Kajosaari LI, et al,. Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin Pharmacol Ther 2005; 78: 388-399. (Pubitemid 41393674)
14. Kalliokoski A, Niemi M,. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 2009; 158: 693-705.
15. Maeda K, Sugiyama Y,. Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs. Drug Metab Pharmacokinet 2008; 23: 223-235.
16. Shitara Y, et al,. Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu Rev Pharmacol Toxicol 2005; 45: 689-723. (Pubitemid 40261822)
17. Shitara Y, et al,. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporine A. J Pharmacol Exp Ther 2003; 304: 610-616. (Pubitemid 36152336)
18. Hirano M, et al,. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos 2006; 34: 1229-1236.
19. Smith PK, et al,. Measurement of protein using bicinchoninic acid. Anal Biochem 1985; 150: 76-85. (Pubitemid 16258399)
20. Tamai I, et al,. Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C. Pharm Res 2001; 18: 1262-1269. (Pubitemid 32846318)
21. Lowry OH, et al,. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275.
22. Hirano M, et al,. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 2004; 311: 139-146. (Pubitemid 39287793)
23. Ishizuka H, et al,. Transport of temocaprilat into rat hepatocytes: role of organic anion transporting polypeptide. J Pharmacol Exp Ther 1998; 287: 37-42. (Pubitemid 29140183)
24. Yamaoka K, et al,. A pharmacokinetic analysis program (MULTI) for microcomputer. J Pharmacobiodyn 1981; 4: 879-885. (Pubitemid 12174128)
25. Ito K, et al,. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 1998; 50: 387-412.
26. Sabia H, et al,. Effect of a selective CYP2C9 inhibitor on the pharmacokinetics of nateglinide in healthy subjects. Eur J Clin Pharmacol 2004; 60: 407-412. (Pubitemid 39214894)
27. Joel G, et al,. Goodman and Gilman's the Pharmacological Basis of Therapeutics, 10th edn. New York: McGraw-Hill, 2001.
28. Kalliokoski A, et al,. The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range. Br J Clin Pharmacol 2008; 66: 818-825.
29. Kalliokoski A, et al,. Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. Pharmacogenet Genomics 2008; 18: 937-942.
30. Zhang W, et al,. Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide. Br J Clin Pharmacol 2006; 62: 567-572. (Pubitemid 44571578)
31. Ismair MG, et al,. Hepatic uptake of cholecystokinin octapeptide by organic anion-transporting polypeptides OATP4 and OATP8 of rat and human liver. Gastroenterology 2001; 121: 1185-1190. (Pubitemid 33022099)
32. Cui Y, et al,. Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem 2001; 30: 9626-9630.
33. International Transporter Consortium, Giacomini KM, et al,. Membrane transporters in drug development. Nat Rev Drug Discov 2010; 9: 215-236.